<?xml version="1.0" ?><text author="Isabelle Solassol, Frédéric Pinguet, Xavier Quantin" dateCollected="2019-11-03" id="autogum_academic_doc035" shortTile="fda-emaapproved-tyrosine" sourceURL="https://www.mdpi.com/2218-273X/9/11/668/htm" speakerCount="0" speakerList="none" title="FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management" type="academic">
<head>
<s>
5
.
</s>
<s>
Conclusions
and
Perspectives
</s>
</head>
<p>
<s>
EGFR-TKIs
are
currently
the
standard
first-line
treatment
of
patients
with
advanced
NSCLC
with
activating
<hi rend="italic">
EGFR
</hi>
mutations
.
</s>
<s>
These
targeted
therapies
are
usually
well
tolerated
comparative
to
conventional
chemotherapy
.
</s>
<s>
The
self-oral
administration
of
the
drug
positively
contributes
to
improving
patient
compliance
and
reducing
the
use
of
hospital
resources
.
</s>
<s>
However
,
this
non-invasive
route
of
administration
is
also
associated
with
unpredictable
bioavailability
,
increased
risk
of
drug
interactions
,
and
concerns
about
patient
safety
,
surveillance
,
and
follow-up
.
</s>
<s>
Chronic
EGFR-TKIs
underdosage
may
favor
the
selection
of
resistant
clones
and
thus
disease
progression
,
and
overdosage
may
increase
the
risk
of
dose-related
side
effects
.
</s>
<s>
Self-administration
also
means
that
the
severity
of
side
effects
can
be
considerably
impacted
by
patient
behavior
(
e.
g.
,
dietary
habits
,
self-medicating
,
smoker
status
)
.
</s>
<s>
To
date
,
EGFR-TKIs
can
be
administered
in
advanced
NSCLC
for
a
long
period
of
time
,
usually
until
the
disease
progresses
or
unacceptable
toxicity
occurs
.
</s>
<s>
As
early
intervention
with
supportive
care
strategies
can
minimize
the
intensity
of
adverse
reactions
or
allow
for
appropriate
dose
adjustments
without
the
need
to
discontinue
treatment
,
acute
toxicity
follow-up
and
side
effect
management
is
of
major
interest
.
</s>
</p>
<p>
<s>
Therefore
,
medical
oncologists
should
not
only
understand
the
AEs
associated
with
these
drugs
,
but
also
develop
the
necessary
skills
to
detect
and
treat
them
to
reduce
morbidity
and
mortality
as
well
as
premature
discontinuation
of
treatment
.
</s>
<s>
Patient
education
on
these
strategies
is
also
of
major
importance
and
can
improve
patient
tolerance
,
quality
of
life
,
and
overall
treatment
outcome
by
initiating
supportive
care
soon
after
symptoms
occur
.
</s>
<s>
Within
this
guidance
and
preventive
strategy
,
the
pharmacist
can
play
a
major
role
.
</s>
<s>
Good
knowledge
of
disease
monitoring
,
response
milestones
,
and
the
risks
versus
benefits
of
the
treatment
options
allows
pharmacists
to
better
advise
patients
or
counsel
patients
more
effectively
.
</s>
<s>
Nurses
and
prescribers
are
qualified
to
monitor
toxicity
risks
as
closely
as
possible
.
</s>
<s>
Unfortunately
,
they
do
not
necessarily
do
so
at
regular
intervals
.
</s>
<s>
Patients
can
connect
with
pharmacists
who
can
provide
them
additional
information
or
complementary
recommendations
on
AEs
without
the
need
for
patients
to
rapidly
contact
prescribers
.
</s>
<s>
When
more
complex
or
serious
AEs
appear
,
pharmacists
who
work
closely
with
nurses
and
prescribers
can
propose
the
most
appropriate
therapeutic
strategies
.
</s>
<s>
Finally
,
medical
oncologists
able
to
understand
AEs
along
with
patient
education
and
collaboration
between
different
medical
professional
groups
for
therapeutic
drug
monitoring
systems
are
needed
,
but
further
research
on
the
aforementioned
methods
of
relief
for
continued
TKI
use
should
be
also
performed
in
the
future
.
</s>
</p>
<p>
<s>
The
importance
of
proactive
patient
follow-up
must
be
emphasized
rather
than
relying
on
self-reporting
between
clinical
visits
.
</s>
<s>
A
randomized
trial
showed
that
patients
receiving
chemotherapy
for
advanced
cancer
,
web-based
symptom
reporting
with
automated
clinician
e-mail
alerts
resulted
in
better
health-related
quality
of
life
,
fewer
emergency
room
visits
,
fewer
hospitalizations
,
and
superior
quality-adjusted
survival
.
</s>
</p>
<p>
<s>
Recently
,
Cheema
et
al.
assessed
the
impact
of
an
interprofessional
,
proactive
follow-up
algorithm
on
the
incidence
of
dose
interruptions
,
reductions
,
and
the
severity
of
AEs
in
patients
on
afatinib
.
</s>
<s>
The
authors
reported
that
over
half
of
first
AEs
and
one
third
of
all
grade
1-2
and
grade
≥3
AEs
were
detected
through
proactive
follow-up
.
</s>
<s>
This
multi-disciplinary
AE
algorithm
resulted
in
a
low
rate
of
costly
emergency
room
or
urgent
clinic
visits
and
a
reduced
incidence
of
severe
drug-related
AEs
and
discontinuation
therapy
.
</s>
</p>
<p>
<s>
In
conclusion
,
when
closely
monitoring
patients
,
the
ability
of
clinicians
to
make
rapid
therapeutic
decisions
in
the
event
of
medical
complications
is
critical
in
the
diagnosis
and
management
of
TKI-related
side
effects
.
</s>
<s>
This
is
even
more
decisive
in
the
event
of
serious
or
even
life-threatening
complications
.
</s>
<s>
However
,
good
clinician
–
patient
communication
,
drug
patient
education
,
early
detection
and
management
of
drug
side
effects
,
and
monitoring
of
disease
response
with
plasma
concentration
quantification
can
also
improve
patient
outcomes
.
</s>
<s>
Close
cooperation
between
oncologists
,
internists
,
pharmaceutics
,
and
nurses
should
become
the
gold
standard
in
the
comprehensive
clinical
care
of
advanced
NSCLC
patients
receiving
TKIs
.
</s>
</p>
</text>